PMID: 28514589Jan 1, 2015Paper

Complications in Transplantation: Medication Nonadherence

Clinical Transplants
Tiffany E Kaiser, Rita R Alloway

Abstract

Following solid organ transplant, complex, lifelong medication regimens are required to prevent allograft rejection. Estimates of medication nonadherence in transplant recipients vary and may be as high as 70%. Poor medication adherence post transplant has been recognized as a contributing factor to reduced outcomes, including rejection, graft loss, and survival. Despite the numerous identified approaches for adherence assessment, there remains no gold standard. Ongoing efforts to identify optimal immunosuppressant adherence monitoring and measuring tools in an attempt to identify at risk populations post transplantation continue; however, the link between this information and outcomes remains to be discovered. Future adherence studies within the transplant population should focus on developing surrogate markers of immunosuppressant therapy adequacy and exploring the association amongst this data, adherence interventions, and outcomes so that optimal strategies may be identified. Immunosuppressant adherence should not be assumed, and interventions aimed a priori will provide opportunities to derail the movement of negative health outcomes resulting from preventable causes.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Progress in Transplantation : Official Publication, North American Transplant Coordinators Organization ... [et Al.]
Lut BerbenSabina De Geest
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Allison TongJonathan C Craig
Transplantation Reviews
Sarah R LieberEyal Shemesh
© 2022 Meta ULC. All rights reserved